

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



1624

#5

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
MARTIN A. HAY	
Type or print name of person signing certification	
	July 11, 2002
Signature	Date

PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : LIEBESCHUETZ, John Walter  
MURRAY, Christopher William  
YOUNG, Stephen Clinton  
CAMP, Nicholas Paul  
JONES, Stuart Donald  
WYLIE, William Alexander  
MASTERS, John Joseph  
WILEY, Michael Robert  
SHEEHAN, Scott Martin  
ENGEL, David Birenbaum  
WATSON, Brian Morgan

RECEIVED  
JUL 15 2003  
TECH CENTER 1600/2900

Serial No. : 10/030,186  
Filed : 04 February 2002  
Group Art Unit: 1624  
Examiner : LIU, Hong  
For : Serine Protease Inhibitors  
Docket No. : 00218/US

By Facsimile (without Copies of References)

Confirmation (with Copies of References) by Courier

Commissioner for Patents  
US Patent & Trademark Office  
2011 South Clark Place  
Customer Window  
Crystal Plaza Two, Lobby, Room 1B03  
UNITED STATES

Sir:

**INFORMATION DISCLOSURE STATEMENT**

As a means of complying with the duty of disclosure, Applicant's submit an "Information Disclosure Statement by Applicant" on PTO Form PTO/SB/08A for consideration by the Examiner. Since this statement is being submitted during the period specified in 37 C.F.R. § 1.97(b), it is believed that no fee is due for this submission. However, should an Office Action on the merits have been mailed, please charge Deposit Account No. 50-1230 in the amount of the fee under 37 C.F.R. § 1.17(p), and consider the information under 37 C.F.R. § 1.97(c).

It is understood that the Examiner has received a copy of the International Search Report and copies of the documents cited therein (Documents B1, B2, B4 and B5). If this is incorrect, the Examiner is kindly requested to contact the undersigned to request copies.

Document A2, which issued in April, 2003, claims priority from the same US provisional application as Document B18.

In addition, Applicants would like to provide the Examiner with the following background information:-

**BACKGROUND INFORMATION**

This application claims priority under 35 U.S.C. 119 from PCT/GB00/02302 (WO 00/76971, Document (B4)), which has entered the U.S. national stage as U.S. patent application serial number 09/926,712. The claims in the 09/926,712 application have been amended so as not to read on any of the compounds originally claimed in the present application.

The compounds claimed in this application were invented in the course of a research collaboration between Eli Lilly and Company (the assignee of record) and Protherics Molecular Design Limited (now Tularik Limited, a subsidiary of Tularik Inc). The predecessor company of Protherics Molecular Design Limited was Proteus Molecular Design Limited.

This application forms part of a portfolio of patent applications directed to serine protease inhibitors, some of which belong to Eli Lilly and Company, and some of which belong to Tularik Limited. The history of this portfolio traces back to a research project on serine protease inhibitors started by Proteus Molecular Design Limited. The undersigned is responsible for handling the applications in this portfolio.

A listing of the co-pending applications and patents in the portfolio is attached.

Eli Lilly and Company also owns a separate portfolio of applications and patents relating to serine protease inhibitors. PCT references belonging to this portfolio are listed in the attached form PTO/SB/08A. Generally these PCT references have U.S. counterparts.

COMMUNICATION BY TELEPHONE

If the Examiner wishes to speak by telephone with the undersigned, the undersigned can be contacted by e-mail at martinahay@martin-a-hay.com, and would be pleased to telephone the Examiner in response.

Respectfully submitted,



Hay, Martin Alexander  
Agent for Applicants  
Registration No. 39,459  
Phone: 011 44 1625 500057  
e-mail: martinahay@martin-a-hay.com

Martin A. Hay & Co.,  
13 Queen Victoria Street  
Macclesfield  
Cheshire  
SK11 6LP  
UNITED KINGDOM

July 11, 2003

Serial No. 10/030,186

**Co-Pending Lilly and Tularik Applications and Patents**

**Co-pending applications - Assigned to Eli Lilly and Company**

09/926,712 (national stage of WO 00/76971 (B4))  
09/926,716 (national stage of WO 00/76970 (B5) - abandoned)  
10/030,187 (national stage of WO 01/96323)  
10/030,188 (national stage of WO 01/96303)  
10/030,189 (national stage of WO 01/96296)

**4. Co-pending applications and patents - Assigned to Tularik Limited**

US 6262069 and US 6420438 (national stage of WO 99/11657 (B1) and continuation)  
09/988,082 (continuation-in-part of 09/485,678, WO 99/11658 (B2) and of WO 00/77027 (B6))  
10/148,174 (national stage of WO 01/44226)  
10/296,245 (national stage of WO 01/96305)  
10/432,365 (national stage of WO 02/47762)







PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	3
-------	---

3

Q

15

**C mplete if Known**

Application Number	10/030.186
--------------------	------------

10/030.186

Filing Date	02/04/2002
-------------	------------

02/04/2002

First Named Inventor	Liebeschuetz, J. W.
----------------------	---------------------

Liebeschuetz, J. W.

Art Unit	1624
----------	------

1624

Examiner Name	LIU, Hong
---------------	-----------

LIU, Hong

Attorney Docket Number	00218/US
------------------------	----------

00218/US
----------

## U. S. PATENT DOCUMENTS

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
	B13	WO 00/39111	07-06-2000	Eli Lilly and Co		
	B14	WO 00/39117	07-06-2000	Eli Lilly and Co		
	B15	WO 00/39118	07-06-2000	Eli Lilly and Co		
	B16	EP 796866A1	09-24-1997	Eli Lilly and Co		
	B17	WO 97/49404	12-31-1997	Eli Lilly and Co		
	B18	WO 00/71493	11-30-2000	Cor Therapeutics		

**Examiner  
Signature**

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



